Lavipharm SA banner
L

Lavipharm SA
ATHEX:LAVI

Watchlist Manager
Lavipharm SA
ATHEX:LAVI
Watchlist
Price: 1.41 EUR 0.86%
Market Cap: €237.9m

Lavipharm SA
Other Current Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Lavipharm SA
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
L
Lavipharm SA
ATHEX:LAVI
Other Current Liabilities
€977k
CAGR 3-Years
131%
CAGR 5-Years
50%
CAGR 10-Years
2%
No Stocks Found

Lavipharm SA
Glance View

Market Cap
237.9m EUR
Industry
Pharmaceuticals

Lavipharm SA engages in the manufacture and import of pharmaceuticals and veterinary products. The company is headquartered in Athina, Attiki. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. The company is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.

LAVI Intrinsic Value
0.66 EUR
Overvaluation 53%
Intrinsic Value
Price €1.41
L

See Also

What is Lavipharm SA's Other Current Liabilities?
Other Current Liabilities
977k EUR

Based on the financial report for Jun 30, 2025, Lavipharm SA's Other Current Liabilities amounts to 977k EUR.

What is Lavipharm SA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
2%

Over the last year, the Other Current Liabilities growth was 215%. The average annual Other Current Liabilities growth rates for Lavipharm SA have been 131% over the past three years , 50% over the past five years , and 2% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett